S'abonner

Platelets constitutively express IL-33 protein and modulate eosinophilic airway inflammation - 09/11/16

Doi : 10.1016/j.jaci.2016.01.032 
Tomohiro Takeda, PhD a, b, , Hirotoshi Unno, MD, PhD b, Hideaki Morita, MD, PhD b, Kyoko Futamura, MD, PhD b, Maiko Emi-Sugie, PhD b, Ken Arae, PhD b, c, Tetsuo Shoda, MD, PhD b, Naoko Okada, PhD b, Arisa Igarashi, PhD b, Eisuke Inoue, PhD d, Hiroshi Kitazawa, MD, PhD e, Susumu Nakae, PhD b, f, g, Hirohisa Saito, MD, PhD b, Kenji Matsumoto, MD, PhD b, , Akio Matsuda, PhD b,
a Department of Health Sciences, Kansai University of Health Sciences, Osaka, Japan 
b Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan 
c Department of Immunology, Faculty of Health Science, Kyorin University, Tokyo, Japan 
d Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan 
e Division of Allergy, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan 
f Laboratory of Systems Biology, Center for Experimental Medicine and Systems Biology, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan 
g Precursory Research for Embryonic Science and Technology (PRESTO), Japan Science and Technology Agency, Saitama, Japan 

Corresponding author: Tomohiro Takeda, PhD, Department of Health Sciences, Kansai University of Health Sciences, 2-11-1, Wakaba, Kumatori, Sennan, 590-0482, Osaka, Japan.Department of Health SciencesKansai University of Health Sciences2-11-1, Wakaba, Kumatori, SennanOsaka590-0482JapanKenji Matsumoto, MD, PhD, Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, 157-8535, Tokyo, Japan.Department of Allergy and Clinical ImmunologyNational Research Institute for Child Health and Development2-10-1 Okura, Setagaya-kuTokyo157-8535JapanAkio Matsuda, PhD, Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, 157-8535, Tokyo, Japan.Department of Allergy and Clinical ImmunologyNational Research Institute for Child Health and Development2-10-1 Okura, Setagaya-kuTokyo157-8535Japan

Abstract

Background

Although platelets play a key role in allergic inflammation in addition to their well-established role in hemostasis, the precise mechanisms of how platelets modulate allergic inflammation are not fully understood. IL-33 is an essential regulator of innate immune responses and allergic inflammation.

Objective

We sought to determine the expression of IL-33 protein by platelets and its functional significance in airway inflammation.

Methods

IL-33 protein in human platelets, the human megakaryocyte cell line MEG-01, and bone marrow–derived mouse megakaryocytes was detected by using Western blot analysis and fluorescent immunostaining. We examined the functional relevance of IL-33 protein in platelets by comparing platelet-intact and platelet-depleted groups in a murine model of IL-33–dependent airway eosinophilia elicited by intranasal administration of papain. We further compared the additive effect of administration of platelets derived from wild-type versus IL-33–deficient mice on the papain-induced eosinophilia.

Results

Platelets and their progenitor cells, megakaryocytes, constitutively expressed IL-33 protein (31 kDa). Papain-induced IL-33–dependent airway eosinophilia in mice was significantly attenuated by platelet depletion. Conversely, concomitant administration of platelets derived from wild-type mice but not IL-33–deficient mice enhanced the papain-induced airway eosinophilia.

Conclusions

Our novel findings suggest that platelets might be important cellular sources of IL-33 protein in vivo and that platelet-derived IL-33 might play a role in airway inflammation. Therefore platelets might become an attractive novel therapeutic target for asthma and probably allergic inflammation.

Le texte complet de cet article est disponible en PDF.

Key words : Airway inflammation, asthma, eosinophil, IL-33, papain, platelet

Abbreviations used : AM, BAL, GAPDH, HBSS, HMVEC-L, ILC2, IL1RL1, IM, MDC, MIP, OVA, qPCR, TARC


Plan


 Supported in part by National Institute of Biomedical Innovation grant ID10-43 (to K.M.), grants from the National Center for Child Health and Development #26-9 (to K.M.) and #26-46 (to M.E.-S.), and JSPS KAKENHI grant no. 23591666 (to A.M.).
 Disclosure of potential conflict of interest: E. Inoue has consultant arrangements with Tokyo Women's Medical University, is employed by Kitasato University, and has received payment for lectures from Merck Serono. H. Saito is employed by the National Center for Child Health & Development, Japan; has received grants from the Ministry of Health, Labour & Welfare, Japan, and the Japan Society for Promotion of Science; has received payment for lectures from Teijin Pharma, Merck Sharp and Dohme KK, Nippon Boehringer Ingelheim, Shiseido, Ono Pharmaceutical, GlaxoSmithKline KK, Pfizer Japan, Novartis Pharma KK, Kyowa Hakko Kirin, Kyorin Pharmaceutical, Daiichi Sankyo, and AstraZeneca KK; has received payment for development of educational presentations from Toho University School of Medicine; and has received travel support from the Japanese Society of Pediatric Allergy & Clinical Immunology, the Japanese Society of Allergology, and the World Allergy Organization. K. Matsumoto has received grants from the National Institute of Biomedical Innovation (Grant ID10-43) and a grant from the National Center for Child Health and Development (#26-9); is employed by the National Research Institute for Child Health and Development; has received payment for lectures from Merck Sharp and Dohme KK, Ono Pharmaceutical, GlaxoSmithKline, Kyorin Pharmaceutical, Ohtsuka Pharmaceutical, Mitsubishi Tanabe Pharma, AstraZeneca KK, Siemens Healthcare, Abbott Japan, Sumitomo Dainippon Pharma, Maruho, and Teijin Pharma; and has received payment for development of educational presentations from Gifu Pharmaceutical University. The rest of the authors declare that they have no relevant conflicts of interest.


© 2016  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 138 - N° 5

P. 1395 - novembre 2016 Retour au numéro
Article précédent Article précédent
  • Dedicator of cytokinesis 8 regulates signal transducer and activator of transcription 3 activation and promotes TH17 cell differentiation
  • Sevgi Keles, Louis Marie Charbonnier, Venkataraman Kabaleeswaran, Ismail Reisli, Ferah Genel, Nesrin Gulez, Waleed Al-Herz, Narayanaswamy Ramesh, Antonio Perez-Atayde, Neslihan E. Karaca, Necil Kutukculer, Hao Wu, Raif S. Geha, Talal A. Chatila
| Article suivant Article suivant
  • High alcohol consumption causes high IgE levels but not high risk of allergic disease
  • Frederikke K. Lomholt, Sune F. Nielsen, Børge G. Nordestgaard

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.